Multi Modality Tumor Tracking qEASL (MMTT qEASL)

Semi-automatic tumor quantification

This semi-automated 3D (Volumetric) tumor response assessment tool, based on EASL (European Association for the Study of the Liver) criteria incorporates functional information from contrast-enhanced scans.

tumor tracking qeasl thumbnail

Benefits

  • Multi Modality Tumor Tracking supports the creation of Quantitative EASL (qEASL) maps used to measure segmented volumes of interest (VOI) in heterogeneous lesions.
  • Data are presented as color map overlaid on the scans to show regional tumor enhancement heterogeneity. The color regions of the segmented lesions are where there is more enhancement than the pre-defined reference region.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

You are entering a Philips Healthcare Australia website
Please select the checkbox

The information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).

By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.

Continue Cancel